AI Stock Analysis - Humacyte (HUMA)
Analysis generated March 12, 2026.
Humacyte is a biotechnology company focused on the development and commercialization of bioengineered human tissues and organs. These innovations aim to address unmet medical needs in vascular, orthopedic, and other tissue-replacement therapies. The company's flagship product is a bioengineered blood vessel, which holds promise for various conditions like vascular trauma and dialysis access.
Stock Alerts - Humacyte (HUMA)
 |
Humacyte | March 10 Price is up by 6.7% in the last 24h. |
|
Humacyte | March 9 Price is up by 7.2% in the last 24h. |
|
Humacyte | March 4 Price is up by 8.4% in the last 24h. |
|
Humacyte | February 27 Price is down by -6.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Humacyte
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 7 | Sign up | Sign up | Sign up |
| Facebook Followers | 425 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 91 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,024 | Sign up | Sign up | Sign up |
| X Followers | 2,708 | Sign up | Sign up | Sign up |
| X Mentions | 47 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 421 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 62 | Sign up | Sign up | Sign up |
| Linkedin Employees | 189 | Sign up | Sign up | Sign up |
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
| Price | $1.14 |
| Target Price | Sign up |
| Volume | 6,595,827 |
| Market Cap | $239M |
| Year Range | $0.89 - $2.73 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price TargetFebruary 18 - Benzinga |
|
Humacyte Reports Data Evaluating Symvess In Extremity Arterial Trauma PatientsFebruary 17 - Benzinga |
|
 |
Humacyte: Positive News For Symvess At Last, But Long-Term Threats PersistFebruary 9 - SeekingAlpha |
Humacyte Announces U.S. Department Of Defense's FY26 Appropriations Act Includes Procurement Of Bioengineered Blood VesselsFebruary 8 - Benzinga |
|
 |
Humacyte announces data from analysis of charges for extremity arterial injuryJanuary 8 - Thefly.com |
|
Humacyte announces planned MAA for Symvess in IsraelJanuary 5 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 750,000 | 260,000 | 490,000 | -18M | -13M | -0.110 |
| Q2 '25 | 300,000 | 2.1M | -1.8M | -38M | -33M | -0.240 |
| Q1 '25 | 520,000 | 2M | -1.5M | 39M | 44M | -0.080 |
| Q4 '24 | 7.2M | 3.6M | 3.6M | -21M | -17M | -0.209 |
| Q3 '24 | 0 | 1.8M | -1.8M | -39M | -35M | -0.330 |
Insider Transactions View All
| Niklason Laura E filed to sell 591,685 shares at $1.6. August 20 '25 |
| Dougan Brady W filed to sell 591,685 shares at $1.6. August 20 '25 |
| Niklason Laura E filed to sell 1,691,685 shares at $1.8. August 20 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Thomas Tuberville Republican |
May 15, 24 | Sell | $50K - $100K |
| Thomas Tuberville Republican |
Apr 15, 24 | Buy | $1K - $15K |
| Thomas Tuberville Republican |
Apr 15, 24 | Buy | $1K - $15K |
Read more about Humacyte (HUMA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Humacyte
The Market Cap of Humacyte is $239M.
Currently, the price of one share of Humacyte stock is $1.14.
The HUMA stock price chart above provides a comprehensive visual representation of Humacyte's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Humacyte shares. Our platform offers an up-to-date HUMA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Humacyte (HUMA) does not offer dividends to its shareholders. Investors interested in Humacyte should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Humacyte are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
